Dow Chemical Sees Heavy Put Trading Ahead of Earnings Release

Dow Chemical experienced heavy put volume, with 12,344 puts trading, or 3x expected. The most active strikes were the 7/25 weekly 25 puts and Dec-25 37.5 calls, with a total volume of near 11,200 contracts. The Put/Call Ratio was 5.27, and ATM IV was up over 3 points on the day. Earnings are expected on July 24th.

Dow Chemical (DOW) experienced significant put volume on Monday, June 19, 2025, with 12,344 puts trading, representing a threefold increase over expected levels. This heavy put volume, coupled with a high put/call ratio of 5.27 and a notable increase in implied volatility (ATM IV up over 3 points), suggests investor caution ahead of the company's earnings report scheduled for July 24, 2025 [1].

The most active strikes were the 7/25 weekly 25 puts and Dec-25 37.5 calls, with a combined volume of nearly 11,200 contracts. This activity indicates that investors are positioning themselves for potential downward movement in the stock price, as evidenced by the high volume of put options, which are typically used to profit from a decline in the underlying asset's price.

Dow Chemical operates in various segments, including Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings, providing materials science solutions for diverse applications globally [2]. The company's extensive portfolio and international reach make it a significant player in the chemical industry.

Investors should closely monitor Dow Chemical's earnings report to gauge the company's performance and the market's reaction to the results. The heavy put volume and increased implied volatility suggest that investors are anticipating potential challenges or uncertainties that could impact the stock price.

References:
[1] https://finance.yahoo.com/quote/DOW/
[2] https://www.tradingview.com/news/reuters.com,2025-06-26:newsml_GNX8R7BBD:0-invivyd-announces-positive-full-phase-1-2-clinical-data-for-vyd2311-a-next-generation-covid-19-monoclonal-antibody-for-potential-use-as-a-non-vaccine-preventative-and-for-treatment-of-active-infection/